Alzheimer's disease: Pathophysiological and pharmacological features;A doença de Alzheimer: Aspectos fisiopatológicos e farmacológicos

Revista de Psiquiatria do Rio Grande do Sul

Volumn 30, Issue 1 SUPPL., 2008, Pages

  Sereniki, Adriana ^b   Vital, Maria Aparecida Barbato Frazão ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b Departamento de Farmacologia ^*

Author keywords

Acetylcholinesterase; Alzheimer's disease; Cyclooxygenase inhibitors; Inflammation

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; ATORVASTATIN; CELECOXIB; CHOLINESTERASE INHIBITOR; CITALOPRAM; CITALOR; DEXAMETHASONE; DIAZEPAM; DONAREN; DONEPEZIL; FLUOXETINE; FLUVOXAMINE MALEATE; GALANTAMINE; IBUPROFEN; IMIPRAMINE; INDOMETACIN; MEVINOLIN; NAPROXEN; PHENELZINE; PRAVACOL; PRAVASTATIN; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; RIVASTIGMINE; ROFECOXIB; SERTRALINE; SIMVASTATIN; STEROID; TACRINE; TRANYLCYPROMINE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGGRESSIVENESS; AGING; ALZHEIMER DISEASE; AMNESIA; DEGENERATIVE DISEASE; DEPRESSION; HALLUCINATION; HISTOPATHOLOGY; HUMAN; NEUROPSYCHIATRY; PATHOPHYSIOLOGY; REVIEW;

EID: 58149253182     PISSN: 01018108     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0101-81082008000200002y     Document Type: Review

References (74)

1. Zhao Q, Tang XC. Effects of huperzine A on an acetylcholinesterase isoforms in vitro: comparison with tacrine, donepezil, rivastigmine and physostigmine. Eur J Pharmacol. 2002;455(2-3):101-7.
2. Janus C, Westaway D. Transgenic mouse models of Alzheimer's disease. Physiol Behav. 2001;73(5):873-86.
3. Lindeboom J, Weinstein H. Neuropsychology of cognitive ageing, minimal cognitive impairment, Alzheimer's disease, and vascular cognitive impairment. Eur J Pharmacol. 2004;490(1-3):83-6.
4. Raskind MA. Alzheimer's disease: treatment of noncognitive behavioural abnormalities. In: Bloom FE, Kupper DJ. Psychopharmacology: the fourth generation of progress. New York: Raven Press; 1995. p. 1427-35.
5. Forlenza OV. Transtornos depressivos na doença de Alzheimer: diagnóstico e tratamento. Rev Bras Psiquiatr. 2000;22(2):87-95.
6. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry. 1989;146(5):577-87.
7. Eastwood R, Reisberg B. Mood and behaviour. In: Gauthier S, editor. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz; 1996. p. 175-90.
8. Selkoe D. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741-66.
9. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353- 6.
10. Bartus RT, Emerich DF. Cholinergic markers in Alzheimer disease. JAMA. 1999;282 (23):2208-9.
11. Auld DS, Kornecook TJ, Bastianetto S, Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition and treatment strategies. Prog Neurobiol. 2002;68(3):209-45.
12. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM. Platelet phospholipase A2 activity in Alzheimer's disease and mild cognitive impairment. J Neural Transm. 2004;111(5):591-601.
13. Gattaz WF, Maras A, Cairns NJ, Levy R, Forstl H. Decreased phospholipase A2 activity in Alzheimer brains. Biol Psychiatry. 1995;37(1):13-7.
14. Gattaz WF, Cairns NJ, Levy R, Forstl H, Braus DF, Maras A. Decreased phospholipase A2 activity in the brain and in platelet of patients with Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci. 1996;246(3):129-31.
15. Gattaz FW, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK. Increased plasma phospholipase A2 activity in schizophrenic patients: reduction after neuroleptic therapy. Biol Psychiatry. 1987;22(4):421-6.
16. Fuentealba RA, Farias G, Scheu J, Bronfman M, Marzolo MP, Inestrosa NC. Signal transduction during amyloid-beta-peptide neurotoxicity: role in Alzheimer disease. Brain Res Brain Res Rev. 2004;47(1-3):275-89.
17. Braak E, Braak H. Alzheimer's disease: transiently developing dendritic changes in pyramidal cells of sector CA1 of the Ammon's horn. Acta Neuropathol (Berl). 1997;93(4):323-5.
18. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, et al. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem. 1999;274(52):37111-6.
19. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM,et al. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 1998;273(21):12817-26.
20. Lowell MA, Robertson JD, Teesdale WJ, Campbell JL, Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 1998;158(1):47-52.
21. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, et al. Aqueous dissolution of Alzheimer's disease abeta amyloid deposits by biometal depletion. J Biol Chem. 1999;274(33):23223-8.
22. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 2001;30(3):665-76.
23. About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (translated by L. Jarvik and H. Greenson). Alzheimer Dis Assoc Disord. 1987;1(1):3-8.
24. Parihar MS, Hemnani T. Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci. 2004;11(5):456-67.
25. Mestel R. Putting prions to the test. Science. 1996;273(5272):184-9.
26. Smith MAC. Doença de Alzheimer. Rev Bras Psiquiatr. 1999;21(Suppl 2):3-7.
27. Malamud N. Neuropathology of organic brain syndromes associated with aging. In: Gaitz CM, editor. Aging and the brain. New York: Plenum Press; 1972. p. 63-87.
28. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA. 1995;92(26):12260-4.
29. Kosunen O, Talasniemi S, Lehtovirta M, Heinonen O, Helisalmi S, Mannermaa A, et al. Relation of coronary atherosclerosis and apolipoprotein E genotypes in Alzheimer patients. Stroke. 1995;26(5):743-8.
30. Citron M. Secretases as targets for the treatment of Alzheimer's disease. Mol Med Today. 2000;6(10):392-7.
31. Kivipelto M, Helkala EL, Hanninen T, Laakso MP, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56(12):1683-9.
32. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med. 2003;9(3):94-101.
33. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356(9242):1627-31.
34. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, et al. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides abeta 42 and abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA. 2001;98(10):5856-61.
35. Moore AH, O'Banion MK. Neuroinflammation and anti-inflammatory therapy for Alzheimer's disease. Adv Drug Deliv Rev. 2002;54(12):1627-56.
36. Perry G, Taddeo MA, Nunomura A, Zhu X, Zenteno-Savin T, Drew KL, et al. Comparative biology and pathology of oxidative stress in Alzheimer and other neurodegenerative diseases: beyond damage and response. Comp Biochem Physiol C Toxicol Pharmacol. 2002;133(4):507-13.
37. Lovell MA, Ehmann WD, Butler SM, Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology. 1995;45(8):1594-601.
38. Dizdaroglu M. Oxidative damage to DNA in mammalian chromatin. Mutat Res. 1992;275(3-6):331-42.
39. Smith MA, Sayre LM, Vitek MP, Monnier VM, Perry G. Early AGEing and Alzheimer's. Nature. 1995;374(6520):316.
40. Stefanis L, Park DS, Friedman WJ, Greene LA. Greene, caspase-dependent and independent death of camptothecin-treated embryonic cortical neurons. J Neurosci. 1999;19(15):6235-47.
41. Parker WD Jr., Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport defects in Alzheimer's disease brain. Neurology. 1994;44(6):1090-6.
42. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol. 2005;37(2):289-305.
43. Brown GC, Bal-Price A. Inflammatory neurodegeneration mediated by nitric oxide, glutamate and mitochondria. Mol Neurobiol. 2003;27(3):325-55.
44. Rogers J, Lue LF. Microglial chemotaxis, activation, and phagocytosis of amyloid betapeptide as linked phenomena in Alzheimer's disease. Neurochem Int. 2001;39(5-6):333-40.
45. Teaktong T, Graham A, Court J, Perry R, Jaros E, Johnson M, et al. Alzheimer's disease is associated with a selective increase in alpha7 nicotinic acetylcholine receptor immunoreactivity in astrocytes. Glia. 2003;41(2):207-11.
46. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Eikelenboom P. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr Drug Targets. 2003;4(6):461-8.
47. Mackenzie IR. Postmortem studies of the effect of anti-inflammatory drugs on Alzheimertype pathology and associated inflammation. Neurobiol Aging. 2001;22(6):819-22.
48. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM. Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res. 1999;57(3):295-303.
49. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic abeta42 independently of cyclooxygenase activity. Nature. 2001;414(6860):212-6.
50. Bate C, Veerhuis R, Eikelenboom P, Williams A. Neurones treated with cyclo-oxygenase-1 inhibitors are resistant to amyloid-beta1-42. Neuroreport. 2003;14(16):2099-103.
51. Kelley KA, Ho L, Winger D, Freire-Moar J, Borelli CB, Aisen PS, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999;155(3):995-1004.
52. Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 2002;1(5):279-84.
53. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819-26.
54. Scali C, Giovannini MG, Prosperi C, Bellucci A, Pepeu G, Casamenti F. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammatory and protects cholinergic neurons from excitotoxic degeneration in vivo. Neuroscience. 2003;117(4):909-19.
55. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
56. Skovronsky DM, Lee VM, Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem. 2001;276(20):17036-43.
57. Hull M, Lieb K, Fiebich BL. Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr Med Chem. 2002;9(1):83-8.
58. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's disease cooperative study. Neurology. 2000;54(3):588-93.
59. Kihara T, Sawada H, Nakamizo T, Kanki R, Yamashita H, Maelicke A, et al. Galantamine modulates nicotinic receptor and blocks abeta-enhanced glutamate toxicity. Biochem Biophys Res Commun. 2004;325(3):976-82.
60. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Curr The Res. 2003;64(4):216-35.
61. Fergusson E, Howard R. Donepezil for the treatment of psychosis in dementia with Lewy bodies. Int J Geriatr Psychiatry. 2000;15(3):280-1.
62. Almeida OP. Tratamento da doença de Alzheimer: avaliação crítica sobre o uso de anticolinesterá sicos. Arq Neuropsiquiatr. 1998;56(3B):688-96.
63. Shao D, Zou C, Luo C, Tang X, Li Y. Synthesis and evaluation of tacrine-E2020 hybrids as acetylcholinesterase inhibitors for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2004;14(18):4639-42.
64. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol. 2000;393(1-3):165-70.
65. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol. 2000;393(1-3):141-6.
66. Zhang Z, Wang X, Chen Q, Shu L, Wang J, Shan G. Clinical efficacy and safety of huperzine Alpha in treatment of mild to moderate Alzheimer disease, a placebo-controlled, double-blind, randomized trial. Zhonghua Yi Xue Za Zhi. 2002;82(14):941-4.
67. De Felice FG, Houzel JC, Garcia-Abreu J, Louzada PR Jr, Afonso RC, Meirelles MN, et al. Inhibition of Alzheimer's disease beta-amyloid aggregation, neurotoxicity, and in vivo deposition by nitrophenols: implications for Alzheimer's therapy. FASEB J. 2001;15(7):1297-9.
68. Louzada PR, Lima AC, Mendonça-Silva DL, Noel F, De Mello FG, Ferreira ST. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptors agonists: activation of GABA receptor and possible implications for Alzheimer's disease and other neurological disorders. FASEB J. 2004;18(3):511-8.
69. De Felice FG, Vieira MN, Saraiva LM, Figueroa-Villar JD, Garcia-Abreu J, Liu R, et al. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J. 2004;18(12):1366-72.
70. Reifler BV, Teri L, Raskind M, Veith R, Barnes R, White E, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry. 1989;146(1):45-9.
71. Knegtering AH, Eijck M, Huijsman A. Effects of antidepressants on cognitive functioning of elderly patients. Drugs Aging. 1994;5(3):192-9.
72. Tune LE. Depression and Alzheimer's disease. Depress Anxiety. 1998;8 Suppl 1:91-5.
73. Nyth AL, Gottfries CG, Lyby K, Smedegaard-Andersen L, Gylding-Sabroe J, Kristensen M, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand. 1992;86(2):138-45.
74. Prudic J, Sackeim HA. Electroconvulsive therapy for mood disorders. Curr Rev Mood Anxiety Disord. 1997;1(3):177-88.